(Q36399557)

14 August 2017

1 reference

title

Epigenetic therapy of cancer: past, present and future (English)

1 reference

14 August 2017

Christine B Yoo

1

1 reference

14 August 2017

Peter A Jones

series ordinal

2

1 reference

14 August 2017

publication date

1 January 2006

1 reference

Nature Reviews Drug Discovery

14 August 2017

published in

1 reference

14 August 2017

volume

5

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

37-50

1 reference

DNA methylation patterns and epigenetic memory

14 August 2017

cites work

1 reference

Comprehensive analysis of CpG islands in human chromosomes 21 and 22

31 March 2020

1 reference

Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms

31 March 2020

1 reference

Genomic structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes

31 March 2020

1 reference

In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation

31 March 2020

1 reference

Translating the Histone Code

31 March 2020

1 reference

The key to development: interpreting the histone code?

31 March 2020

1 reference

Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly

31 March 2020

1 reference

A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin

31 March 2020

1 reference

Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains

31 March 2020

1 reference

Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin

31 March 2020

1 reference

The role of DNA methylation in setting up chromatin structure during development

31 March 2020

1 reference

Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis

31 March 2020

1 reference

Causes and consequences of DNA hypomethylation in human cancer

31 March 2020

1 reference

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

31 March 2020

1 reference

The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma

31 March 2020

1 reference

Suppression of intestinal neoplasia by DNA hypomethylation.

31 March 2020

1 reference

Hypomethylation distinguishes genes of some human cancers from their normal counterparts

31 March 2020

1 reference

5-Methylcytosine, Gene Regulation, and Cancer

31 March 2020

1 reference

Chromosomal Instability and Tumors Promoted by DNA Hypomethylation

31 March 2020

1 reference

Induction of Tumors in Mice by Genomic Hypomethylation

31 March 2020

1 reference

Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach.

31 March 2020

1 reference

Preferential response of cancer cells to zebularine.

31 March 2020

1 reference

Aberrant CpG-island methylation has non-random and tumour-type-specific patterns.

31 March 2020

1 reference

CpG island methylator phenotype in colorectal cancer

31 March 2020

1 reference

Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells

31 March 2020

1 reference

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

31 March 2020

1 reference

Global histone modification patterns predict risk of prostate cancer recurrence

31 March 2020

1 reference

Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9.

31 March 2020

1 reference

A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response.

31 March 2020

1 reference

Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase

31 March 2020

1 reference

Histone demethylation mediated by the nuclear amine oxidase homolog LSD1

31 March 2020

1 reference

LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription

31 March 2020

1 reference

Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases.

31 March 2020

1 reference

HhaI methyltransferase flips its target base out of the DNA helix

31 March 2020

1 reference

On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs

31 March 2020

1 reference

Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine

31 March 2020

1 reference

Zebularine: A Novel DNA Methylation Inhibitor that Forms a Covalent Complex with DNA Methyltransferases

31 March 2020

1 reference

5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal

31 March 2020

1 reference

Trapped in action: direct visualization of DNA methyltransferase activity in living cells.

31 March 2020

1 reference

Cellular differentiation, cytidine analogs and DNA methylation

31 March 2020

1 reference

Multiple new phenotypes induced in and 3T3 cells treated with 5-azacytidine

31 March 2020

1 reference

High-performance Liquid Chromatographic Analysis of Chemical Stability of 5-aza-2′-Deoxycytidine

31 March 2020

1 reference

Kinetics and Mechanisms of Degradation of the Antileukemic Agent 5‐Azacytidine in Aqueous Solutions

31 March 2020

1 reference

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

31 March 2020

1 reference

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

31 March 2020

1 reference

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

31 March 2020

1 reference

Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine).

31 March 2020

1 reference

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

31 March 2020

1 reference

Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.

31 March 2020

1 reference

Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine

31 March 2020

1 reference

Contrasting Cytotoxicity Kinetics of 5-Azacytidine and Dihydro-5-azacytidine Hydrochloride in L1210 Leukemia in Mice2, 3

31 March 2020

1 reference

Micronuclei induced by modulators of methylation: analogs of 5-azacytidine.

31 March 2020

1 reference

Biochemical pharmacology and DNA methylation studies of arabinosyl 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell lines PER-145 and PER-163.

31 March 2020

1 reference

Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice

31 March 2020

1 reference

Direct identification of the active-site nucleophile in a DNA (cytosine-5)-methyltransferase

31 March 2020

1 reference

Improved synthesis of zebularine [1-(beta-D-ribofuranosyl)-dihydropyrimidin-2-one] nucleotides as inhibitors of human deoxycytidylate deaminase

31 March 2020

1 reference

Binding of pyrimidin-2-one ribonucleoside by cytidine deaminase as the transition-state analogue 3,4-dihydrouridine and the contribution of the 4-hydroxyl group to its binding affinity

31 March 2020

1 reference

Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase

31 March 2020

1 reference

Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase

31 March 2020

1 reference

Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.

31 March 2020

1 reference

Mutagenicity of the cytidine analog zebularine in Escherichia coli

31 March 2020

1 reference

Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine

31 March 2020

1 reference

Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases.

31 March 2020

1 reference

In living color: DNA methyltransferase caught in the act

31 March 2020

1 reference

Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks

31 March 2020

1 reference

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly

31 March 2020

1 reference

Psammaplins from the Sponge Pseudoceratina purpurea: Inhibition of Both Histone Deacetylase and DNA Methyltransferase

31 March 2020

1 reference

Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression

31 March 2020

1 reference

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

31 March 2020

1 reference

Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine.

31 March 2020

1 reference

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

31 March 2020

1 reference

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

31 March 2020

1 reference

Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.

31 March 2020

1 reference

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

31 March 2020

1 reference

Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas

31 March 2020

1 reference

Valproic acid inhibits angiogenesis in vitro and in vivo

31 March 2020

1 reference

Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB.

31 March 2020

1 reference

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

31 March 2020

1 reference

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

31 March 2020

1 reference

Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation

31 March 2020

1 reference

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

31 March 2020

1 reference

Sodium butyrate inhibits histone deacetylation in cultured cells

31 March 2020

1 reference

The effect of sodium butyrate on histone modification

31 March 2020

1 reference

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

31 March 2020

1 reference

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

31 March 2020

1 reference

Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines.

31 March 2020

1 reference

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

31 March 2020

1 reference

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

31 March 2020

1 reference

Histone deacetylase inhibitors

31 March 2020

1 reference

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

31 March 2020

1 reference

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

31 March 2020

1 reference

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

31 March 2020

1 reference

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

31 March 2020

1 reference

The Discovery of NVP-LAQ824: From Concept to Clinic

31 March 2020

1 reference

Structure, histone deacetylase, and antiprotozoal activities of apicidins B and C, congeners of apicidin with proline and valine substitutions

31 March 2020

1 reference

Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones

31 March 2020

1 reference

Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases.

31 March 2020

1 reference

Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.

31 March 2020

1 reference

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

31 March 2020

1 reference

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

31 March 2020

1 reference

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma

31 March 2020

1 reference

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors

31 March 2020

1 reference

Chronic oral administration of CI-994: a phase 1 study

31 March 2020

1 reference

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine

31 March 2020

1 reference

Zebularine: a new drug for epigenetic therapy

31 March 2020

1 reference

Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix

31 March 2020

1 reference

A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer

31 March 2020

1 reference

The power and the promise of DNA methylation markers

31 March 2020

1 reference

A crack in histone lysine methylation.

31 March 2020

1 reference

The language of covalent histone modifications

31 March 2020

1 reference

Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome.

31 March 2020

1 reference

The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote

31 March 2020

1 reference

Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14.

31 March 2020

1 reference

Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins

31 March 2020

1 reference

Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L

31 March 2020

1 reference

Dnmt3L and the establishment of maternal genomic imprints

31 March 2020

1 reference

Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes

31 March 2020

1 reference

Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins

31 March 2020

1 reference

Unsafe SETs: histone lysine methyltransferases and cancer

31 March 2020

1 reference

Histone methylation in transcriptional control

31 March 2020

1 reference

Reversing histone methylation

31 March 2020

1 reference

Continuous Infusion of 5-Azacytidine as Induction for Acute Nonlymphocytic Leukemia in Patients with Previous Exposure to 5-Azacytidine

31 March 2020

1 reference

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

31 March 2020

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

31 March 2020

1 reference

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation

31 March 2020

1 reference

Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly

31 March 2020

1 reference

Modulation of angiogenesis-related protein synthesis by valproic acid

31 March 2020

1 reference

Phase I trial of continuous infusion 5-aza-2'-deoxycytidine

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1930

1 reference

Dimensions Publication ID

14 August 2017

1021896263

0 references

1 reference